

A practical guide for providers on helping patients locate Gloperba. Includes pharmacy strategies, tools, alternative prescribing, and workflow tips.
When patients can't fill their Gloperba prescription, they often turn to their prescriber for help. As a provider, you're in a unique position to facilitate access — whether that means helping locate the medication, navigating insurance barriers, or making a clinically appropriate switch. This guide offers practical, actionable strategies for your practice.
Gloperba (Colchicine oral solution, 0.6 mg/5 mL) is the only FDA-approved liquid Colchicine. It's produced by a single manufacturer, carries a wholesale price of $500–$700+ per month, and many retail pharmacies don't stock it due to low demand and high cost. Patients who need it — particularly those with dysphagia or feeding tubes — often face a frustrating search.
For a comprehensive overview of the supply challenges, see Gloperba Shortage: What Providers and Prescribers Need to Know in 2026.
Before investing time in a search, confirm whether the patient specifically needs the liquid formulation:
If the patient can safely take tablets, generic Colchicine 0.6 mg tablets are widely available and cost-effective. This is the simplest path forward. If the liquid form is medically necessary, proceed with the strategies below.
The most efficient tool for locating Gloperba in real time is MedFinder. Have your front desk or care coordination staff provide patients with this resource. They can search by zip code to find pharmacies that currently have Gloperba in stock.
For provider-specific tools and features, visit medfinder.com/providers.
Specialty pharmacies are significantly more likely to stock or have rapid access to niche medications like Gloperba. Consider these approaches:
Hospital outpatient pharmacies are another often-overlooked resource. If your practice is affiliated with a hospital system, check if their outpatient pharmacy stocks Gloperba.
If a patient's preferred pharmacy doesn't have Gloperba in stock, the pharmacy can often order it from their wholesaler. This typically takes 1–3 business days. You can facilitate this process by:
Insurance is often the biggest hurdle. Many plans either don't cover Gloperba or require prior authorization with step therapy through tablet Colchicine first. Practical steps:
If PA is denied, consider a peer-to-peer review. Having the clinical rationale clearly documented strengthens your case. Key talking points:
Some plans may grant a formulary exception when medical necessity is established. Work with the plan's pharmacy benefit manager and provide supporting documentation.
If Gloperba is truly unavailable and the patient needs a liquid, compounded Colchicine is the primary fallback. Best practices:
If Colchicine in any form is inaccessible, review the patient's gout prophylaxis regimen. Alternatives include:
For detailed clinical alternatives, see Gloperba Shortage: What Providers and Prescribers Need to Know in 2026.
To reduce the burden on your practice when patients can't find Gloperba:
Even when Gloperba is available, cost can be a barrier. Resources to share with patients:
For a comprehensive patient-facing cost guide, refer patients to How to Save Money on Gloperba in 2026. For a provider-focused savings guide, see How to Help Patients Save Money on Gloperba: Provider's Guide.
Helping patients find Gloperba requires a multi-step approach: verify the need for a liquid, leverage tools like MedFinder for Providers, engage specialty pharmacies, navigate insurance, and have a compounding backup plan. Building a standardized workflow for Gloperba access saves time and ensures your patients don't go without gout prophylaxis.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.